| pubmed-article:16846409 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16846409 | lifeskim:mentions | umls-concept:C0543467 | lld:lifeskim |
| pubmed-article:16846409 | lifeskim:mentions | umls-concept:C0019080 | lld:lifeskim |
| pubmed-article:16846409 | lifeskim:mentions | umls-concept:C0010055 | lld:lifeskim |
| pubmed-article:16846409 | lifeskim:mentions | umls-concept:C0003641 | lld:lifeskim |
| pubmed-article:16846409 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:16846409 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:16846409 | lifeskim:mentions | umls-concept:C0547040 | lld:lifeskim |
| pubmed-article:16846409 | lifeskim:mentions | umls-concept:C0040044 | lld:lifeskim |
| pubmed-article:16846409 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:16846409 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:16846409 | pubmed:dateCreated | 2006-7-18 | lld:pubmed |
| pubmed-article:16846409 | pubmed:abstractText | To determine whether 500,000 KIU aprotinin is effective to reduce blood loss in coronary artery bypass grafting (CABG) and to evaluate the effects of this regimen on hematologic parameters. | lld:pubmed |
| pubmed-article:16846409 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16846409 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16846409 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16846409 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16846409 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16846409 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16846409 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16846409 | pubmed:issn | 0886-0440 | lld:pubmed |
| pubmed-article:16846409 | pubmed:author | pubmed-author:CatavZekiZ | lld:pubmed |
| pubmed-article:16846409 | pubmed:author | pubmed-author:SenerErolE | lld:pubmed |
| pubmed-article:16846409 | pubmed:author | pubmed-author:EmirMustafaM | lld:pubmed |
| pubmed-article:16846409 | pubmed:author | pubmed-author:TasdemirOguzO | lld:pubmed |
| pubmed-article:16846409 | pubmed:author | pubmed-author:CagliKerimK | lld:pubmed |
| pubmed-article:16846409 | pubmed:author | pubmed-author:TopbasMuratM | lld:pubmed |
| pubmed-article:16846409 | pubmed:author | pubmed-author:CicekciogluFe... | lld:pubmed |
| pubmed-article:16846409 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16846409 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:16846409 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16846409 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16846409 | pubmed:pagination | 336-41 | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:meshHeading | pubmed-meshheading:16846409... | lld:pubmed |
| pubmed-article:16846409 | pubmed:articleTitle | Effects of minimal dose aprotinin on blood loss and fibrinolytic system-complement activation in coronary artery bypass grafting surgery. | lld:pubmed |
| pubmed-article:16846409 | pubmed:affiliation | Cardiovascular Surgery Clinic, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey. | lld:pubmed |
| pubmed-article:16846409 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16846409 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16846409 | lld:pubmed |
